On December 1, 2020 Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, reported that it has been granted a new patent from the European Patent Office (EPO) (Press release, Calidi Biotherapeutics, DEC 1, 2020, View Source [SID1234572049]). European Patent Number 3209382, "Combination Immunotherapy Approach for Treatment of Cancer," secures Calidi’s proprietary technology platform, Supernova 1 (SNV1), composed of the oncolytic agent, CAL1 vaccinia virus, loaded into allogeneic, adipose-derived mesenchymal stem cells (AD-MSC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re very excited to be granted this European Patent to protect our innovative immunotherapy product and combination approach abroad," said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics. "This new patent provides considerable opportunity for the expansion of Calidi’s years of research into the profound oncolytic potential of SNV1."
Pre-clinical data has shown Calidi’s SVN1 product to shield the viral payload of CAL1 vaccinia virus from the patient’s immune system, supporting efficient delivery to tumor sites and effectively potentiating oncolytic viruses.
"Our talented, seasoned team of doctors and scientists have exerted years of intensive research and groundbreaking work to produce Calidi’s SVN1 technology," said Boris Minev, MD, President, Medical and Scientific Affairs at Calidi Biotherapeutics. "This patent represents the culmination of their impressive expertise, dedication, and passion."
As of the EP Grant Date, November 25, 2020, the European Patent covers Calidi’s combination immunotherapy approach and SNV1 product in 37 contracting European countries. Earlier in the year, the patent was also granted in Canada, Russia, Singapore, Australia, and New Zealand.